AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of ...
A psychedelic therapy being developed by atai Life Sciences and Beckley Psytech has met its primary endpoint in a Phase IIb study in patients with treatment-resistant depression. The nasal spray, ...
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative ...
Anavex (AVXL) Life Sciences announced the publication “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback